Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
journal names
Pharmacology & Toxicology
Top-3 citing journals

Pharmacology & Toxicology
(935 citations)

European Journal of Pharmacology
(748 citations)

Toxicology
(429 citations)
Top-3 organizations

Karolinska Institute
(124 publications)

University of Copenhagen
(98 publications)

University of Helsinki
(84 publications)
Most cited in 5 years
Found
Publications found: 463
Q3

Isolation of Nutmeg Essential Oil (Myristica fragrans houtt) From Aceh Indonesia and Their Antioxidant and Antibacterial Activities
Khairan K., Faradilla M., Ginting B.
This study aims to isolate the nutmeg essential oil (Myristica fragrans Houtt) from Aceh Indonesia and evaluate their biological activity. The antioxidant activity of the nutmeg essential oils (Myristica fragrans Houtt) was determined by DPPH (1,1-difenil-2-pikrihidrazil) assay. The DPPH assay showed that arillus essential oil (AMFH) has the highest antioxidant activity with the IC50 values was 216,695 ppm. The chemical composition of the AMFH was perfomed by Gas Chromatography-Mass Spectroscopy (GC-MS), and the results showed that AMFH contains Terpinen-4-ol (T-4-ol), α-Terpineol (α-T), Safrole (Saf) and Myristicin (Myr) with the percentage area of 11.20%; 1.83%; 5.10%; and 27.80% respectively. The AMFH was isolated by column chromatography and four fractions were obtained, namely AMFH1; AMFH2; AMFH3; and AMFH4 fractions. The DPPH assay showed that the AMFH3 fraction showed excellent antioxidant activity with the IC50 values of 59.329 ppm. The AMFH3 fraction was than reisolated by using by column chromatography to obtain four subfractions namely AMFH3A; AMFH3B; AMFH3C; and AMFH3D. The DPPH assay showed that the subfraction of AMFH3A has the highest antioxidant activity with the IC50 values of 98.993 ppm. The antibacterial activity of AMFH3A subfractions was evaluated by Kirby Bauer-Disc diffusion method, and the results showed that AMFH3A subfraction showed slightly higher activity against Staphylococcus epidermidis and Staphylococcus aureus with the diameter inhibition of 14.28 mm and 12.26 mm respectively. The chemical composition of the AMFH3A subfraction was performed by GC-MS, and the results showed that AMFH3A subfraction contains Terpinen-4-ol (T-4-ol), α-Terpineol (α-T), Safrole (Saf) and Myristicin (Myr) with the percentage area of 14.37%; 2.16%; 7.36%; and 54.77% respectively.
Q3

Zinc Sulfate and α-tocopherol Supplementation Enhance Reproductive Performance in Male Albino Rats (Rattus norvegicus) With Lead Acetate Toxicity
Prastiya R.A., Sardjito T., Agustono B., Fikri F., Saputro A.L., Wurlina W., Dewi B.L., Pratiwi S.M., Nugroho A.P., Moses I.B.
Metal toxicity from lead affects reproductive organ function by activating reactive oxygen species processes. This study aims to see how α-tocopherol and zinc sulfate (ZnSO4) affect gonads, liver, follicle-stimulating hormone, luteinizing hormone, spermatogenesis (the amount of spermatogonia, spermatocytes, and spermatids), and Leydig cells in male albino rats (Rattus norvegicus) exposed to lead acetate Pb(CH3COO)2. The samples used were 25 male Wistar rats aged 4 months, separated into five groups. For 30 days, all treatment groups were exposed to Pb(CH3COO)2 at a level of 50-mg/kg body weight (BW). The T1 group was given a dosage of 100-mg/kg BW of α-tocopherol. The ZnSO4 was given to the T2 group at a dose of 0.54-mg/kg BW. Meanwhile, the T3 group was given a mixture of ZnSO4 at 0.54-mg/kg BW and α-tocopherol at 100-mg/kg BW orally. ELISA test was carried out to determine the level of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in a blood plasma sample of 100 μl / 1 mg. Histopathological observations made on the liver included counting damaged cells and seminiferous tubules that included counting the amount of spermatogonia, spermatocytes, spermatids, Sertoli cells, and Leydig cells. Using SPSS 20 software, the collected data were analyzed using analysis of variance, followed by Duncan’s test with a 95% simultaneous confidence level. The highest average levels of FSH and LH in the T3 group were 3.6162 mIU/mL and 14.9658 mIU/mL. The finding showed that Pb(CH3COO)2 caused disruptions in the spermatogenesis and Leydig cell processes. Exogenous antioxidants in combination with ZnSO4 and α-tocopherol had significant effect on enhancing reproductive performance in animals exposed to Pb(CH3COO)2.
Q3

Clinical Decision Support Systems to Identify Drug-Related Problems in Diabetes Mellitus Patients: A Systematic Review
Larasati N., Satibi S., Kristina S.A., Lazuardi L.
Clinical Decision Support Systems (CDSSs) has been developed for utilization to provide rational therapy to Diabetes Mellitus (DM) patients including preventing Drug-related Problems (DRPs) such as the effect of drug treatment being not optimal, untreated indications and symptoms, unnecessary therapy, and adverse drug reactions. This study aims to summarize the available evidence on the intervention of CDSSs, key outputs, and impact of the user in DM patients. This study was a systematic review using PubMed, Scopus database, and by manually searching the bibliographies of articles that have been found. We included studies reporting on evaluated CDSSs that had been implemented in medication prescription, reducing medication errors, adverse drug events, drug-allergy checking, drug dosing support, and so on. A total of 8 studies were selected among 855 studies. CDSSs are used in hospitals and primary care settings to identify potential drug interactions, correct therapy regimens, monitor therapy, blood glucose documentation, ensure patients receive medication according to the guideline, provide nutritional advice, and schedule physical activity. The usage of CDSSs improves blood glucose levels, detects possible drug interactions, reduces face-to-face consultations, improves documentation, assists in identifying dose, and promotes prescribing in line with the guideline. The use of CDSSs can help to reduce the risk of errors in management therapy.
Q3

Comparative Cellular and In Vivo Anti-cancer studies of Doxorubicin Liposomes Prepared with Different Types of Phospholipids
Miatmoko A., Cahyani D.M., Kawano K., Hattori Y.
The selection of lipid components of membrane bilayer determines the rigidity of liposomes affecting drug efficacy, especially for cancer drug delivery. The present study evaluated liposomes with different rigidity for delivering doxorubicin (DOX). In this work, liposomes composed of rigid lipid, hydrogenated soybean phosphatidylcholine (HSPC), were totally or partially substituted with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). The liposomes are composed of phosphatidylcholine (HSPC, POPC), with and without combination with DOPE, cholesterol, and DSPE-mPEG2000 with a molar ratio of 57: 38: 5, respectively. Liposomes were prepared using a thin layer hydration method. Then, in vitro cytotoxicity and in vivo antitumor activity of these liposomes were evaluated. Substitution of HSPC with POPC resulted in similar cytotoxicities profiles similar to the DOX solution on C26 colon cancer cells and LLC cells. The DOPE addition to DOX liposomes reduced the antitumor activity. In conclusion, the lipid substitution of HSPC with POPC or DOPE reduced liposome rigidity; however, it lowered the in vivo antitumor activity.
Q3

Simultaneous Quantification of Ramipril and Ramiprilat in Drug Formulations: A Clinical LC-MS/MS Study
Omari K., Abu-Awwad A., Arafat B., Macovei G., Boltez T., Abdel Baki Z., Mallah E., Arafat T.
Ramipril is a drug controlling hypertension. Two drugs were studied in 36 healthy adults. The drugs are the test (Atb®) and the reference (Tritace®). This concept is crucial in the pharmaceutical industry during the development process. The maximum concentration (Cmax) of Ramipril and its metabolite (Ramiprilat) were determined throughout drug administration in healthy subjects. All analysis was performed using LC-MS/MS. The method was validated over a range of 0.200 – 25.000 ng/mL in which linearity (R2) was 0.9983, accuracy was 99.9%, precision (CV) was less than 20%, and the Lower Limit of Quantitation was 0.200 ng/mL. Stability and other parameters were discussed. The time needed to reach this concentration (Tmax) and the time-drug concentration area under the curve (AUC) were most agreed upon. The two drugs were proven to be interchangeable. Both have similar pharmacokinetics and bioequivalence profiles. Consequently, the drugs are bioequivalent and considered alternatives to one another pharmaceutically. For example, 90% confidence intervals (C.I.) for the in-tra-individual ratios (test/reference) for pharmacokinetic parameters were Cmax, and AUC0-t for total exposure C.I. Log – transformed Values were 80-125 %.
Q3

Phytochemical, Nutraceutical and Pharmacological Aspects of the Philippine native Acalypha angatensis Blanco, Fl. Filip.
Hipol R.L., Wayas H., Bacuyag F.M., Daquigan M., Hipol R., Cabanlong J.
The genus Acalypha has valuable species that have significant pharmaceutical applications. This study investigated the phytochemical composition and thin layer chromatography (TLC) profile, as well as the antioxidant and antibacterial activities of the ethanolic extract of Acalypha pulogensis Sagun & G.A. Levin, an endemic species in the Philippines. Qualitative phytochemical screening revealed the presence of tannins, phenolics, flavonoids, saponins, steroids, and triterpenoids. Nutrient analysis showed that potassium and calcium content were at 1499 mg/100 g and 1380 mg/100 g, respectively. The determination of the total phenolic content (TPC) showed that this species has an average of 282.24 ± 3.56 mg GAE/g and a total flavonoid content (TFC) of 36.24 ± 3.77 mg QE/g of dried extract. These values were found to be higher than those of other Acalypha species. Antioxidant activity was measured using DPPH antioxidant assay, and the extract showed a concentration-dependent radical scavenging effect with an IC50 of 34.02 µg/mL. Antibacterial activity was evaluated using various concentrations against drug-resistant Gram-positive and Gram-negative bacteria using a resazurin-based assay. The ethanolic extract exhibited substantial antibacterial activity against Enterococcus faecium (NCTC 12204) and MRSA (ATCC 33592), with a minimum inhibitory concentration (MIC) of 4 mg/mL. Higher concentrations (>20 mg/mL) were needed for inhibition of the Gram-negative strains (Klebsiella pneumoniae and Enterobacter cloacae). These results suggest that A. pulogensis has good antioxidant and antibacterial activities that support its use in traditional medicine.
Q3

Physico-Chemical and Structural Characterization of Mixed Natural Polymer Hydrogels Under Simulated Gastrointestinal Fluid
Hastuti A.A., Zai K., Risdanareni P., Karolina R., Mustafa I.
The gastrointestinal track has a varied pH, from an acidic pH in the stomach to a slightly basic pH in the intestine. The pH difference creates problems for the delivery of drugs and nutrients, as the active compounds may not survive the changing pH. Incorporating active ingredients into hydrogels can protect the compounds from degradation. Natural polymer hydrogel is preferable because of its safety and compatibility. However, a suitable formula should be optimized to facilitate suitable delivery in the gastrointestinal track. In this study, we produced hydrogels with 10 different formulas of mixed natural polymers: CMC (C), alginate (A), chitosan (X), and/or guar gum (G). The resulting hydrogels were characterized using swelling performance tests at pH 2 and 6.8, Fourier-transform infrared spectroscopy (FTIR), and scanning electron microscopy (SEM). Hydrogels with the formula of C50A25X25, C25A50X25, C25A50G25, C25A25G50, C25A50X12.5G12.5, and C25A25X25G25 are not digested at pH 2, but those hydrogels are digested at pH 6.8. The FTIR spectra of the hydrogels show functional groups of O–H, C=O, C–O, and C–H. Meanwhile, the SEM results show cracking phenomena on the surface of the hydrogels C50A25X12.5G12.5, C25A50X12.5G12.5, and C25A25X25G25. This study offers a general guide for the development of a natural polymer hydrogel as a suitable nutrient vehicle in the gastrointestinal track. Formulation of each type of nutrient should be optimized for optimum delivery to the designated part of the gastrointestinal track.
Q3

Gut Microbiota Dynamics and Phenotypic Changes Induced by Tetracycline in Drosophila melanogaster
Saadjad Z.P., Sartini S., Chairatunnisa R., Latada N.P., Mudjahid M., Nainu F.
Gut microbiota plays a crucial role in both physiological and pathological processes in humans and animals. Antibiotics, designed to combat bacterial infections, can induce alterations in the composition and abundance of the gut microbiota over prolonged exposure. This study addresses the limited understanding of the connections between gut microbiota and phenotypic profiles of metazoan species. We investigated the impact of early-life exposure to tetracycline in wild-type D. melanogaster, which were fed a standard diet, comparing them to a control group not exposed to tetracycline. The primary objective was to examine the consequences of early-life tetracycline exposure on gut microbiota and its implications for phenotypic profiles, including survival, locomotor activity, and reproduction in adult flies. Results revealed a significant reduction in lactic acid bacteria in adult flies exposed to tetracycline. However, tetracycline exhibited no interference with fly development, allowing them to maintain a normal lifespan. In adult flies, tetracycline significantly decreased the lifespan on day 35 at a concentration of 1000 µg/mL and reduced locomotion on day 27 at concentrations of 10 µg/mL and 1000 µg/mL. Remarkably, tetracycline did not impact the reproductive capabilities of the flies. This study demonstrates that while tetracycline led to a decline in lactic acid bacteria, locomotion, and lifespan in adult flies, it did not disrupt their development or reproductive processes.
Q3

Analytical Method Validation and Simultaneous Determination of Ketotifen Fumarate and Cyproheptadine Hydrochloride in Divided Powder by RP-HPLC Method
Dewi M.S., Riswanto F.D., Yuliani S.H.
Ketotifen fumarate and cyproheptadine HCl are the most popular prescription for children at “X” hospital in Yogyakarta. The interest for studying this divided powder was related to the stability test towards human health. Hence, it was important to developed a validated analytical method to quantify content of active drug from sample. In this study, a reversed phase HPLC (RP-HPLC) method was validated and applied for determining content of ketotifen fumarate and cyproheptadine hydrochloride in divided powder. The developed RP-HPLC method was met the requirement of selectivity and sensitivity. Calibration curve formulas of ketotifen fumarate and cyproheptadine hydrochloride were y = 27714x-79111 (r=0.9945) and y = 26324x+72581 (r=0.9935) in the range of 10.9-54.5 and 10.6-53.0 µg/mL, respectively. Accuracy and intermediate precision were assessed on both standard solution and samples spiked with standard solution of ketotifen fumarate and cyproheptadine hydrochloride. It was found that both standard solution and the spiked samples solution were met the requirement of recovery of 80-110% and RSD of less than 7.3% for intraday and interday analysis. Content of ketotifen fumarate and cyproheptadine hydrochloride in sample (n=7) were 16.574±0.098 and 30.640±0.035 µg/mL, respectively. It can be concluded that the RP-HPLC method was successfully validated and applied in the determination of ketotifen fumarate and cyproheptadine hydrochloride in divided powder.
Q3

Formulation of Lotion with Ethanol Extract of Curcuma manga Val. as UV B Sunscreen and Activity Test using UV-Vis Spectrophotometry
Kusumorini N., Zulkarnain A.K.
Temu mango (Curcuma manga Val) is a rhizome plant native to Indonesia that contains curcuminoid and flavonoid antioxidant compounds. These compounds are thought to have activity as UV light protectors, especially UV B. This study uses a qualitative test of the compound content in temu mango followed by formulation and activity testing of water in oil (w/o) sunscreen lotion of temu mango in vitro. Optimization of w/o lotion formulation uses Design Expert® (DE) software version 9.0.4.1 with the Simplex Lattice Design method. The DE software obtained 13 runs of w/o lotion formula and continued with physical properties evaluation to determine the optimum formula. The optimum formula of lotion w/o predicted by DE software was tested for physical stability for four weeks, SPF test, percent pigmentation, and percent erythema using UV-Vis spectrophotometry. The results of the study show that temu mango extract was found to provide an SPF value at a concentration of 0.3 mg/mL with an SPF value of 16.62. The results of the optimum formula of lotion w/o were 7%glycerin, 7% cera alba, 5% cetyl alcohol with a value of stickiness of 0.70 ± 0.03 seconds, spreadability of 13.20 ± 0.83 cm2, and viscosity of 95.19 ± 3.06 dPa.s. Referring to the storage results, the optimum formula of w/o lotion from temu mango extract was stable during one month of storage. The w/o lotion in the optimum formula produced an SPF value of 15.06 ± 0.39, percent erythema of 10.95%, and percent pigmentation of 10.41%.
Q3

Beta-Blocker in Heart Rate Control and Cardio Protection: The Role of ADRB1 Variants and HCN4 Regulation – A Systematic Review
Niruri R., Ikawati Z., Nugroho A.E., Arifianto H.
Elevated heart rate is linked to adverse cardiovascular outcomes. Sinoatrial (SA) nodes, hyperpolarization-activated cyclic nucleotide-gated-4 (HCN4) channels, and beta1-adrenergic receptor (ADRB1) are responsible for generating the heart rate. Beta-blockers have a cardioprotective effect on heart failure, including controlling heart rate. However, the responses to beta-blockers can vary among individuals. ADRB1 genetic variability may be contributed to the differential beta-blocker effect in heart failure. HCN4 also performs a crucial function in the pacemaker cells of the heart. Exploring the effect of beta-blockers in pacemaker cells is expanding the view of their role and their therapeutic response in heart failure. The objectives of this study were to identify ADRB1 genetic variants affecting heart rate response in heart failure subjects with beta-blocker treatment and to explore the effect of beta-blockers on HCN4 channels and SA nodes. A systematic review was performed using three databases. Eight of 668 manuscripts were selected. The systematic review found that ADRB1 genetic variants (A145G (Ser49Gly) and C1165G (Arg389Gly)) can affect heart rate response in beta-blocker-treated heart failure. The study also found that the percentage of patients with the Ser49Ser-Gly389X haplotype achieved a heart rate target was higher than other haplotypes. Individuals with the Arg389Arg genotype necessitated a markedly increased amount of beta-blocker dose to reach the identical heart rate target compared to those with the Gly389X gene variation. In addition, the review found that carvedilol, a beta-blocker derivative, demonstrated beneficial effects in inhibiting HCN-gated channels. Bisoprolol and carvedilol improved channel regulation in the SA Node by reversing the downregulation of HCN4 and sodium channels. In general, this systematic review provides important insights into beta-blockers in treating heart failure, specifically concerning the genetic variability of ADRB1 and the beta-blockers effect on the SA node and HCN4 channels.
Q3

The Role of Growth Differentiation Factor-15 in the Diagnosis of Patients with Chronic Angina Undergoing Coronary Angiography
Butti A., Abbas W.A., Hasan A.Y.
Coronary artery disease (CAD) is considered the most prevalent leading cause of myocardial ischemia and mortality worldwide and can lead to angina pectoris and myocardial infarction (MI). Growth Differentiation Factor-15 (GDF-15) is usually measured together with other biomarkers to predict all-cause mortality. During stressful conditions associated with tissue injury and inflammation like myocardial ischemia, it is released into circulation and detected at high concentration in foam cells of the atherosclerotic plaque. Its circulating levels are associated with chronic diseases rather than acute diseases mainly cardiovascular diseases (CVDs) like CAD and chronic heart failure (CHF). The aim of the current study was to detect the role of GDF-15 as a new biomarker for the diagnosis of stable angina patients with normal left ventricular ejection fraction who were presented as having stable chest pain, so that to avoid endangering them to the invasive coronary angiography. Fasting venous blood samples were taken from 90 participants who were presented as having chest pain. They were all subjected to echocardiography, electrocardiography and coronary angiography. The left ventricular ejection fraction was calculated using the biplane M mode method. GDF-15 serum level was measured by using Human GDF-15 Sandwich ELISA Kit following the manufacturer’s instructions.The current study detected a high significant difference in the serum levels of GDF-15 and serum creatinine between the patients and the control group (P≤0.01). On the other hand, there were significant differences in the serum levels of triglycerides and VLDL-C between both study groups (P≤0.05). ROC curve analysis showed that GDF-15 had AUC= 1.00, the best cut off= 254.16 with sensitivity and specificity of 100%. So, it can be concluded that GDF-15 could be used as a biomarker for the diagnosis of stable angina patients with obstructive atherosclerotic plaque and normal LV ejection fraction.
Q3

Validation of An HPLC Method for the Determination of Some Β-Lactams Antibiotics Using A Green Analytical Technique
Nguyen T.D., Phuong A.T., Truong Quoc K.
Green analytical chemistry (GAC) primary goal is to develop environmental and health-friendly analytical methods by reduction or replacement of hazardous substances from analytical procedures. In this research, the application of GAC to quantify five β-lactams antibiotics (cefuroxime sodium, cefaclor, ertapenem sodium, ampicillin sodium and sulbactam sodium) by high-performance liquid chromatography (HPLC) using photodiode arrays (PDA) detector was developed. To achieve this, ethanol was used as a green replacement for methanol and acetonitrile, common solvents in chromatographic procedures. Several chromatographic conditions were investigated to accomplish the optimal conditions. The method validation followed the ICH Q2 (R1) guideline, and the developed method was successfully applied for quantifying some pharmaceutical products.
Q3

PyPLIF HIPPOS-aided Construction and Retrospective Validation of Structure-Based Virtual Screening Protocol Targeting VEGFR2
Supanji S., Perdamaian A.B., Marsifah T., Istighfari Jenie R., Ikawati M., Kartikawati Paramita D., Perdana Istyastono E.
Recently, the discovery of small molecules as inhibitors for vascular endothelial growth factor receptor 2 (VEGFR2) is of timely interest, especially in the area of ocular neovascular diseases. On the other hand, PyPLIF HIPPOS in combination with machine learning techniques has been reported to increase the prediction quality of structure-based virtual screening (SBVS) protocols. The original version of PyPLIF has served in the development of an SBVS protocol that successfully identified novel chalcone derivatives and short peptides as potent inhibitors for acetylcholinesterase. In this short communication, construction and retrospective validation of an SBVS protocol employing PyPLIF HIPPOS targeting VEGFR2 are presented to make it publicly available. The retrospective validation employed 409 active compounds and 24,950 decoys from the enhanced version of the directory of useful decoys. All compounds were docked independently 3 times using AutoDock Vina followed by the identification of the protein-ligand interaction fingerprints (PLIF) employing PyPLIF HIPPOS. The derived ensemble PLIF descriptors were then used in the decision tree construction using a machine-learning technique called recursive partitioning and regression trees. The best decision was then incorporated in the SBVS protocol. The F-measure and enrichment factor values of the SBVS protocol were 0.387 and 76.879, respectively. Hence, the SBVS protocol is readily available to screen small molecules or short peptides.
Q3

Optimizing the Formula of Polymeric-Based Aripiprazole Nanosuspension Using Response Surface Methodology for Intranasal Drug Delivery
Aisiah N.F., Surini S.
This study aimed to optimize the formula of aripiprazole nanosuspension for intranasal drug delivery. Response Surface Methodology (RSM) was employed to determine the influence of independent variables, including drug concentration, polymer concentration, and the ratio of polymer combination, on the nanosuspension characteristics. The parameters under investigation were particle size (d mean), polydispersity index, and drug content. Fifteen formulas were prepared using the high-shear homogenization–ultrasonication method, and the Design Expert software was applied for optimum formula determination. The result showed significant effects of the independent variables on the nanosuspension characteristics, with particle sizes ranging from 143.6 – 334.6 nm, PDI values of 0.302 – 0.649, and drug content was 98.7 – 102.1 %. The predicted optimum formula had a drug concentration of 28 mg/mL in the organic solvent, polymer concentration of 1.5% (w/v), and HPMC to PVP ratio of 1.4 with desirability of 0.94. Additionally, it exhibited desirable characteristics, such as a particle size of 171.2 11.4 nm, a PDI value of 0.317 0.02, and a high drug content of 100.04 0.65%. In conclusion, the presented methodology appeared to be perfect for the optimization of the aripiprazole nanosuspension formula to ensure suitability for nose-to-brain drug delivery.
Top-100
Citing journals
100
200
300
400
500
600
700
800
900
1000
|
|
Pharmacology & Toxicology
935 citations, 2.19%
|
|
European Journal of Pharmacology
748 citations, 1.75%
|
|
Toxicology
429 citations, 1.01%
|
|
Pharmacology Biochemistry and Behavior
401 citations, 0.94%
|
|
Brain Research
375 citations, 0.88%
|
|
British Journal of Pharmacology
364 citations, 0.85%
|
|
Life Sciences
361 citations, 0.85%
|
|
Toxicology and Applied Pharmacology
353 citations, 0.83%
|
|
Toxicology Letters
321 citations, 0.75%
|
|
Food and Chemical Toxicology
277 citations, 0.65%
|
|
Biochemical Pharmacology
276 citations, 0.65%
|
|
Psychopharmacology
273 citations, 0.64%
|
|
Journal of Pharmacology and Experimental Therapeutics
260 citations, 0.61%
|
|
Archives of Toxicology
229 citations, 0.54%
|
|
Environmental Health Perspectives
221 citations, 0.52%
|
|
Basic and Clinical Pharmacology and Toxicology
206 citations, 0.48%
|
|
Neuropharmacology
201 citations, 0.47%
|
|
Toxicology in Vitro
191 citations, 0.45%
|
|
PLoS ONE
188 citations, 0.44%
|
|
Chemosphere
181 citations, 0.42%
|
|
International Journal of Molecular Sciences
176 citations, 0.41%
|
|
Drug Metabolism and Disposition
174 citations, 0.41%
|
|
Chemico-Biological Interactions
168 citations, 0.39%
|
|
Behavioural Brain Research
165 citations, 0.39%
|
|
Environmental Toxicology and Pharmacology
165 citations, 0.39%
|
|
Neuroscience
163 citations, 0.38%
|
|
British Journal of Clinical Pharmacology
160 citations, 0.37%
|
|
Human and Experimental Toxicology
159 citations, 0.37%
|
|
NeuroToxicology
158 citations, 0.37%
|
|
Critical Reviews in Toxicology
155 citations, 0.36%
|
|
Toxicological Sciences
146 citations, 0.34%
|
|
Biological Trace Element Research
145 citations, 0.34%
|
|
Journal of Biological Chemistry
144 citations, 0.34%
|
|
Journal of Applied Toxicology
138 citations, 0.32%
|
|
Pharmacology and Therapeutics
131 citations, 0.31%
|
|
Journal of Neurochemistry
127 citations, 0.3%
|
|
Journal of Ethnopharmacology
125 citations, 0.29%
|
|
Neuroscience Letters
123 citations, 0.29%
|
|
Anesthesia and Analgesia
121 citations, 0.28%
|
|
Molecules
120 citations, 0.28%
|
|
Science of the Total Environment
119 citations, 0.28%
|
|
Neurotoxicology and Teratology
118 citations, 0.28%
|
|
Progress in Neuro-Psychopharmacology and Biological Psychiatry
116 citations, 0.27%
|
|
Annals of the New York Academy of Sciences
114 citations, 0.27%
|
|
Journal of Pharmacy and Pharmacology
111 citations, 0.26%
|
|
General Pharmacology The Vascular System
110 citations, 0.26%
|
|
Toxicon
109 citations, 0.26%
|
|
Free Radical Biology and Medicine
109 citations, 0.26%
|
|
Xenobiotica
109 citations, 0.26%
|
|
Biochemical and Biophysical Research Communications
107 citations, 0.25%
|
|
Journal of Medicinal Chemistry
102 citations, 0.24%
|
|
Toxicology and Industrial Health
102 citations, 0.24%
|
|
Environmental Research
99 citations, 0.23%
|
|
Ecotoxicology and Environmental Safety
96 citations, 0.22%
|
|
Aquatic Toxicology
94 citations, 0.22%
|
|
Journal of Neural Transmission
93 citations, 0.22%
|
|
Clinical Pharmacokinetics
92 citations, 0.22%
|
|
Journal of Clinical Pharmacology
91 citations, 0.21%
|
|
Reproductive Toxicology
88 citations, 0.21%
|
|
American Journal of Physiology - Heart and Circulatory Physiology
88 citations, 0.21%
|
|
Regulatory Toxicology and Pharmacology
87 citations, 0.2%
|
|
Scientific Reports
87 citations, 0.2%
|
|
Frontiers in Pharmacology
86 citations, 0.2%
|
|
Drug Metabolism Reviews
85 citations, 0.2%
|
|
Handbook of Experimental Pharmacology
85 citations, 0.2%
|
|
Molecular Pharmacology
85 citations, 0.2%
|
|
Naunyn-Schmiedeberg's Archives of Pharmacology
84 citations, 0.2%
|
|
European Neuropsychopharmacology
84 citations, 0.2%
|
|
Environmental Science and Pollution Research
84 citations, 0.2%
|
|
Peptides
81 citations, 0.19%
|
|
Pharmacological Research
80 citations, 0.19%
|
|
Toxicologic Pathology
80 citations, 0.19%
|
|
Pharmacological Reviews
79 citations, 0.19%
|
|
International Journal of Toxicology
79 citations, 0.19%
|
|
European Journal of Clinical Pharmacology
79 citations, 0.19%
|
|
Pain
77 citations, 0.18%
|
|
Neurotoxicity Research
77 citations, 0.18%
|
|
Environmental Science & Technology
76 citations, 0.18%
|
|
Biomedicine and Pharmacotherapy
76 citations, 0.18%
|
|
Alcoholism: Clinical and Experimental Research
75 citations, 0.18%
|
|
Neuroscience and Biobehavioral Reviews
75 citations, 0.18%
|
|
Brain Research Bulletin
75 citations, 0.18%
|
|
Journal of Pharmaceutical Sciences
75 citations, 0.18%
|
|
Biological Psychiatry
74 citations, 0.17%
|
|
Journal of Inorganic Biochemistry
74 citations, 0.17%
|
|
Mutation Research - Genetic Toxicology and Environmental Mutagenesis
74 citations, 0.17%
|
|
Phytotherapy Research
74 citations, 0.17%
|
|
Alcohol
73 citations, 0.17%
|
|
Synapse
73 citations, 0.17%
|
|
Experimental and Toxicologic Pathology
72 citations, 0.17%
|
|
Journal of Cardiovascular Pharmacology
70 citations, 0.16%
|
|
Journal of Toxicology and Environmental Health - Part A: Current Issues
69 citations, 0.16%
|
|
Drug and Chemical Toxicology
69 citations, 0.16%
|
|
Regulatory Peptides
69 citations, 0.16%
|
|
Journal of Pharmaceutical and Biomedical Analysis
68 citations, 0.16%
|
|
Neuropsychopharmacology
67 citations, 0.16%
|
|
Neurochemical Research
66 citations, 0.15%
|
|
Environmental Toxicology and Chemistry
66 citations, 0.15%
|
|
Chemical Research in Toxicology
65 citations, 0.15%
|
|
Neurochemistry International
65 citations, 0.15%
|
|
Show all (70 more) | |
100
200
300
400
500
600
700
800
900
1000
|
Citing publishers
2000
4000
6000
8000
10000
12000
14000
16000
|
|
Elsevier
15483 citations, 36.28%
|
|
Wiley
6688 citations, 15.67%
|
|
Springer Nature
4890 citations, 11.46%
|
|
Taylor & Francis
2490 citations, 5.83%
|
|
Ovid Technologies (Wolters Kluwer Health)
1188 citations, 2.78%
|
|
SAGE
1001 citations, 2.35%
|
|
MDPI
924 citations, 2.17%
|
|
American Chemical Society (ACS)
614 citations, 1.44%
|
|
Oxford University Press
469 citations, 1.1%
|
|
American Society for Pharmacology and Experimental Therapeutics
442 citations, 1.04%
|
|
American Physiological Society
407 citations, 0.95%
|
|
Frontiers Media S.A.
353 citations, 0.83%
|
|
Royal Society of Chemistry (RSC)
261 citations, 0.61%
|
|
Hindawi Limited
237 citations, 0.56%
|
|
Public Library of Science (PLoS)
225 citations, 0.53%
|
|
Environmental Health Perspectives
222 citations, 0.52%
|
|
Mary Ann Liebert
178 citations, 0.42%
|
|
American Society for Biochemistry and Molecular Biology
170 citations, 0.4%
|
|
Cambridge University Press
160 citations, 0.37%
|
|
Walter de Gruyter
117 citations, 0.27%
|
|
S. Karger AG
116 citations, 0.27%
|
|
Georg Thieme Verlag KG
107 citations, 0.25%
|
|
Pharmaceutical Society of Japan
106 citations, 0.25%
|
|
Bentham Science Publishers Ltd.
94 citations, 0.22%
|
|
Canadian Science Publishing
91 citations, 0.21%
|
|
Cold Spring Harbor Laboratory
88 citations, 0.21%
|
|
The Endocrine Society
67 citations, 0.16%
|
|
BMJ
67 citations, 0.16%
|
|
Spandidos Publications
63 citations, 0.15%
|
|
Society for Neuroscience
59 citations, 0.14%
|
|
American Society for Microbiology
58 citations, 0.14%
|
|
Baishideng Publishing Group
58 citations, 0.14%
|
|
American Society for Nutrition
55 citations, 0.13%
|
|
Pleiades Publishing
54 citations, 0.13%
|
|
Science Alert
52 citations, 0.12%
|
|
46 citations, 0.11%
|
|
Federation of American Societies for Experimental Biology (FASEB)
46 citations, 0.11%
|
|
Proceedings of the National Academy of Sciences (PNAS)
45 citations, 0.11%
|
|
American Association for Cancer Research (AACR)
44 citations, 0.1%
|
|
Japanese Society of Toxicology
42 citations, 0.1%
|
|
Pharmaceutical Society of Korea
41 citations, 0.1%
|
|
SciELO
39 citations, 0.09%
|
|
Annual Reviews
38 citations, 0.09%
|
|
World Scientific
32 citations, 0.07%
|
|
American Thoracic Society
32 citations, 0.07%
|
|
28 citations, 0.07%
|
|
King Saud University
26 citations, 0.06%
|
|
Portland Press
24 citations, 0.06%
|
|
American Veterinary Medical Association
24 citations, 0.06%
|
|
IOP Publishing
22 citations, 0.05%
|
|
Japan Society for Occupational Health
22 citations, 0.05%
|
|
The Company of Biologists
21 citations, 0.05%
|
|
American Association for the Advancement of Science (AAAS)
19 citations, 0.04%
|
|
American Academy of Pediatrics
19 citations, 0.04%
|
|
Korean Society of Food Science and Nutrition
19 citations, 0.04%
|
|
American Psychological Association (APA)
19 citations, 0.04%
|
|
IntechOpen
19 citations, 0.04%
|
|
Massachusetts Medical Society
18 citations, 0.04%
|
|
Akademiai Kiado
18 citations, 0.04%
|
|
Scientific Research Publishing
18 citations, 0.04%
|
|
IOS Press
17 citations, 0.04%
|
|
Medknow
17 citations, 0.04%
|
|
American Diabetes Association
16 citations, 0.04%
|
|
Vydavatelstvi Karolinum
16 citations, 0.04%
|
|
Impact Journals
15 citations, 0.04%
|
|
American Society of Clinical Oncology (ASCO)
14 citations, 0.03%
|
|
Asian Network for Scientific Information
14 citations, 0.03%
|
|
American Society of Hematology
14 citations, 0.03%
|
|
American Society for Clinical Investigation
13 citations, 0.03%
|
|
Korean Association of Medical Journal Editors
13 citations, 0.03%
|
|
Tohoku University Medical Press
13 citations, 0.03%
|
|
Universita Palackeho Olomouc
13 citations, 0.03%
|
|
Institute of Electrical and Electronics Engineers (IEEE)
13 citations, 0.03%
|
|
CSIRO Publishing
13 citations, 0.03%
|
|
12 citations, 0.03%
|
|
American Association for Clinical Chemistry
12 citations, 0.03%
|
|
Bioscientifica
12 citations, 0.03%
|
|
The Japanese Circulation Society
11 citations, 0.03%
|
|
The American Association of Immunologists
11 citations, 0.03%
|
|
Rockefeller University Press
9 citations, 0.02%
|
|
International Union of Crystallography (IUCr)
9 citations, 0.02%
|
|
9 citations, 0.02%
|
|
Society for the Study of Reproduction
9 citations, 0.02%
|
|
9 citations, 0.02%
|
|
PeerJ
8 citations, 0.02%
|
|
Eco-Vector LLC
8 citations, 0.02%
|
|
Journal of Neurosurgery Publishing Group (JNSPG)
8 citations, 0.02%
|
|
Australian Society of Anaesthetists
8 citations, 0.02%
|
|
International Association for Food Protection
8 citations, 0.02%
|
|
Instituto de Tecnologia do Parana
8 citations, 0.02%
|
|
Academic Journals
8 citations, 0.02%
|
|
Mark Allen Group
8 citations, 0.02%
|
|
Maad Rayan Publishing Company
8 citations, 0.02%
|
|
Media Sphere Publishing House
8 citations, 0.02%
|
|
Brieflands
8 citations, 0.02%
|
|
The Royal Society
7 citations, 0.02%
|
|
American College of Allergy, Asthma, & Immunology
7 citations, 0.02%
|
|
Institute for Medical Research and Occupational Health
7 citations, 0.02%
|
|
Nofer Institute of Occupational Medicine
7 citations, 0.02%
|
|
American Society of Animal Science
7 citations, 0.02%
|
|
Show all (70 more) | |
2000
4000
6000
8000
10000
12000
14000
16000
|
Publishing organizations
20
40
60
80
100
120
140
|
|
Karolinska Institute
124 publications, 4.56%
|
|
University of Copenhagen
98 publications, 3.61%
|
|
University of Helsinki
84 publications, 3.09%
|
|
Uppsala University
68 publications, 2.5%
|
|
Lund University
65 publications, 2.39%
|
|
University of Eastern Finland
48 publications, 1.77%
|
|
Aarhus University
47 publications, 1.73%
|
|
University of Oslo
44 publications, 1.62%
|
|
Swedish University of Agricultural Sciences
40 publications, 1.47%
|
|
Skåne University Hospital
38 publications, 1.4%
|
|
Karolinska University Hospital
37 publications, 1.36%
|
|
University of Gothenburg
37 publications, 1.36%
|
|
Tampere University
36 publications, 1.32%
|
|
Umeå University
35 publications, 1.29%
|
|
University of Oulu
29 publications, 1.07%
|
|
Tehran University of Medical Sciences
24 publications, 0.88%
|
|
University of Turku
24 publications, 0.88%
|
|
Stockholm University
22 publications, 0.81%
|
|
Linköping University
22 publications, 0.81%
|
|
Uppsala University Hospital
19 publications, 0.7%
|
|
Linköping University Hospital
17 publications, 0.63%
|
|
UiT The Arctic University of Norway
16 publications, 0.59%
|
|
French Institute of Health and Medical Research
16 publications, 0.59%
|
|
University of Bergen
14 publications, 0.52%
|
|
Novo Nordisk
14 publications, 0.52%
|
|
Wonkwang University
14 publications, 0.52%
|
|
Norwegian University of Science and Technology
13 publications, 0.48%
|
|
Oslo University Hospital
13 publications, 0.48%
|
|
Vanderbilt University
13 publications, 0.48%
|
|
University of British Columbia
13 publications, 0.48%
|
|
Indian Institute of Toxicology Research
12 publications, 0.44%
|
|
Technion – Israel Institute of Technology
12 publications, 0.44%
|
|
Helsinki University Hospital
12 publications, 0.44%
|
|
Université Catholique de Louvain
12 publications, 0.44%
|
|
Tampere University Hospital
11 publications, 0.4%
|
|
University of Washington
11 publications, 0.4%
|
|
University of Tartu
11 publications, 0.4%
|
|
Post graduate Institute of Medical Education and Research
10 publications, 0.37%
|
|
Free University of Berlin
10 publications, 0.37%
|
|
University of Southern Denmark
10 publications, 0.37%
|
|
Odense University Hospital
10 publications, 0.37%
|
|
University of Sydney
10 publications, 0.37%
|
|
Hokkaido University
10 publications, 0.37%
|
|
Kiel University
10 publications, 0.37%
|
|
St. Marianna University School of Medicine
10 publications, 0.37%
|
|
Yamaguchi University
10 publications, 0.37%
|
|
University of Barcelona
10 publications, 0.37%
|
|
University of São Paulo
9 publications, 0.33%
|
|
University of Milan
8 publications, 0.29%
|
|
Copenhagen University Hospital
8 publications, 0.29%
|
|
Aarhus University Hospital
8 publications, 0.29%
|
|
Universidad Complutense de Madrid
8 publications, 0.29%
|
|
Institute for Medical Research and Occupational Health
8 publications, 0.29%
|
|
Universidad de Chile
8 publications, 0.29%
|
|
National University of Singapore
7 publications, 0.26%
|
|
Rutgers, The State University of New Jersey
7 publications, 0.26%
|
|
University of Lübeck
7 publications, 0.26%
|
|
East Carolina University
7 publications, 0.26%
|
|
Niigata University
7 publications, 0.26%
|
|
International Agency for Research on Cancer
7 publications, 0.26%
|
|
Federal University of Santa Maria
7 publications, 0.26%
|
|
Tel Aviv University
6 publications, 0.22%
|
|
Rambam Health Care Campus
6 publications, 0.22%
|
|
University Hospital of Umeå
6 publications, 0.22%
|
|
University of Padua
6 publications, 0.22%
|
|
University of Tsukuba
6 publications, 0.22%
|
|
University of Pavia
6 publications, 0.22%
|
|
University of Catania
6 publications, 0.22%
|
|
University of Iceland
6 publications, 0.22%
|
|
University of California, Los Angeles
6 publications, 0.22%
|
|
National Institute for Public Health and the Environment
6 publications, 0.22%
|
|
Hokkaido University of Science
6 publications, 0.22%
|
|
University of Shizuoka
6 publications, 0.22%
|
|
National Institute of Environmental Health Sciences
6 publications, 0.22%
|
|
Universidade Federal do Ceará
6 publications, 0.22%
|
|
University of Madras
5 publications, 0.18%
|
|
Heidelberg University
5 publications, 0.18%
|
|
Jordan University of Science and Technology
5 publications, 0.18%
|
|
University of Bern
5 publications, 0.18%
|
|
Turku University Hospital
5 publications, 0.18%
|
|
Norwegian Institute of Public Health
5 publications, 0.18%
|
|
National Taiwan University
5 publications, 0.18%
|
|
University of Modena and Reggio Emilia
5 publications, 0.18%
|
|
Charles University
5 publications, 0.18%
|
|
Chinese University of Hong Kong
5 publications, 0.18%
|
|
University of California, Davis
5 publications, 0.18%
|
|
Southern Illinois University School of Medicine
5 publications, 0.18%
|
|
University of Michigan
5 publications, 0.18%
|
|
University of Minnesota
5 publications, 0.18%
|
|
Rhenish Friedrich Wilhelm University of Bonn
5 publications, 0.18%
|
|
University of Tokyo
5 publications, 0.18%
|
|
Universidade Estadual de Campinas
5 publications, 0.18%
|
|
University of Toronto
5 publications, 0.18%
|
|
University of Granada
5 publications, 0.18%
|
|
University of Galway
5 publications, 0.18%
|
|
Aligarh Muslim University
4 publications, 0.15%
|
|
University of Lisbon
4 publications, 0.15%
|
|
Radboud University Nijmegen
4 publications, 0.15%
|
|
University of Zurich
4 publications, 0.15%
|
|
University of Lausanne
4 publications, 0.15%
|
|
Show all (70 more) | |
20
40
60
80
100
120
140
|
Publishing countries
100
200
300
400
500
600
|
|
Sweden
|
Sweden, 519, 19.1%
Sweden
519 publications, 19.1%
|
Denmark
|
Denmark, 390, 14.35%
Denmark
390 publications, 14.35%
|
USA
|
USA, 252, 9.27%
USA
252 publications, 9.27%
|
Finland
|
Finland, 235, 8.65%
Finland
235 publications, 8.65%
|
Japan
|
Japan, 182, 6.7%
Japan
182 publications, 6.7%
|
Norway
|
Norway, 164, 6.04%
Norway
164 publications, 6.04%
|
Germany
|
Germany, 97, 3.57%
Germany
97 publications, 3.57%
|
Italy
|
Italy, 73, 2.69%
Italy
73 publications, 2.69%
|
United Kingdom
|
United Kingdom, 67, 2.47%
United Kingdom
67 publications, 2.47%
|
France
|
France, 56, 2.06%
France
56 publications, 2.06%
|
Spain
|
Spain, 55, 2.02%
Spain
55 publications, 2.02%
|
India
|
India, 49, 1.8%
India
49 publications, 1.8%
|
Brazil
|
Brazil, 39, 1.44%
Brazil
39 publications, 1.44%
|
China
|
China, 35, 1.29%
China
35 publications, 1.29%
|
Canada
|
Canada, 35, 1.29%
Canada
35 publications, 1.29%
|
Netherlands
|
Netherlands, 30, 1.1%
Netherlands
30 publications, 1.1%
|
Switzerland
|
Switzerland, 29, 1.07%
Switzerland
29 publications, 1.07%
|
Iran
|
Iran, 27, 0.99%
Iran
27 publications, 0.99%
|
Australia
|
Australia, 26, 0.96%
Australia
26 publications, 0.96%
|
Republic of Korea
|
Republic of Korea, 26, 0.96%
Republic of Korea
26 publications, 0.96%
|
Poland
|
Poland, 24, 0.88%
Poland
24 publications, 0.88%
|
Belgium
|
Belgium, 23, 0.85%
Belgium
23 publications, 0.85%
|
Israel
|
Israel, 23, 0.85%
Israel
23 publications, 0.85%
|
Czech Republic
|
Czech Republic, 13, 0.48%
Czech Republic
13 publications, 0.48%
|
Estonia
|
Estonia, 12, 0.44%
Estonia
12 publications, 0.44%
|
Portugal
|
Portugal, 11, 0.4%
Portugal
11 publications, 0.4%
|
Turkey
|
Turkey, 10, 0.37%
Turkey
10 publications, 0.37%
|
Hungary
|
Hungary, 9, 0.33%
Hungary
9 publications, 0.33%
|
Mexico
|
Mexico, 9, 0.33%
Mexico
9 publications, 0.33%
|
Croatia
|
Croatia, 9, 0.33%
Croatia
9 publications, 0.33%
|
Chile
|
Chile, 8, 0.29%
Chile
8 publications, 0.29%
|
Argentina
|
Argentina, 7, 0.26%
Argentina
7 publications, 0.26%
|
Greece
|
Greece, 7, 0.26%
Greece
7 publications, 0.26%
|
Nigeria
|
Nigeria, 7, 0.26%
Nigeria
7 publications, 0.26%
|
Singapore
|
Singapore, 7, 0.26%
Singapore
7 publications, 0.26%
|
Austria
|
Austria, 6, 0.22%
Austria
6 publications, 0.22%
|
Jordan
|
Jordan, 6, 0.22%
Jordan
6 publications, 0.22%
|
Ireland
|
Ireland, 6, 0.22%
Ireland
6 publications, 0.22%
|
Iceland
|
Iceland, 6, 0.22%
Iceland
6 publications, 0.22%
|
Slovakia
|
Slovakia, 6, 0.22%
Slovakia
6 publications, 0.22%
|
Yugoslavia
|
Yugoslavia, 6, 0.22%
Yugoslavia
6 publications, 0.22%
|
Bulgaria
|
Bulgaria, 5, 0.18%
Bulgaria
5 publications, 0.18%
|
New Zealand
|
New Zealand, 4, 0.15%
New Zealand
4 publications, 0.15%
|
Saudi Arabia
|
Saudi Arabia, 4, 0.15%
Saudi Arabia
4 publications, 0.15%
|
Serbia
|
Serbia, 4, 0.15%
Serbia
4 publications, 0.15%
|
Russia
|
Russia, 3, 0.11%
Russia
3 publications, 0.11%
|
Egypt
|
Egypt, 3, 0.11%
Egypt
3 publications, 0.11%
|
Malaysia
|
Malaysia, 3, 0.11%
Malaysia
3 publications, 0.11%
|
Slovenia
|
Slovenia, 3, 0.11%
Slovenia
3 publications, 0.11%
|
Czechoslovakia
|
Czechoslovakia, 3, 0.11%
Czechoslovakia
3 publications, 0.11%
|
Venezuela
|
Venezuela, 2, 0.07%
Venezuela
2 publications, 0.07%
|
Iraq
|
Iraq, 2, 0.07%
Iraq
2 publications, 0.07%
|
Lebanon
|
Lebanon, 2, 0.07%
Lebanon
2 publications, 0.07%
|
Libya
|
Libya, 2, 0.07%
Libya
2 publications, 0.07%
|
USSR
|
USSR, 2, 0.07%
USSR
2 publications, 0.07%
|
Belarus
|
Belarus, 1, 0.04%
Belarus
1 publication, 0.04%
|
Ghana
|
Ghana, 1, 0.04%
Ghana
1 publication, 0.04%
|
Zimbabwe
|
Zimbabwe, 1, 0.04%
Zimbabwe
1 publication, 0.04%
|
Colombia
|
Colombia, 1, 0.04%
Colombia
1 publication, 0.04%
|
Latvia
|
Latvia, 1, 0.04%
Latvia
1 publication, 0.04%
|
Pakistan
|
Pakistan, 1, 0.04%
Pakistan
1 publication, 0.04%
|
Thailand
|
Thailand, 1, 0.04%
Thailand
1 publication, 0.04%
|
Montenegro
|
Montenegro, 1, 0.04%
Montenegro
1 publication, 0.04%
|
Ethiopia
|
Ethiopia, 1, 0.04%
Ethiopia
1 publication, 0.04%
|
Show all (34 more) | |
100
200
300
400
500
600
|
1 profile journal article
Ozturk Yusuf
🥼
PhD in Pharmacy, Professor

Istanbul Aydin University
90 publications,
1 718 citations
h-index: 24
Research interests
Pharmacology
Pharmacy
1 profile journal article
Meisel Leonor
24 publications,
1 023 citations
h-index: 15